Get the Stockscreener App
1.79
5.29%
0.09
After Hours:
1.76
-0.03
-1.68%
Inhibikase Therapeutics Inc stock is traded at $1.79, with a volume of 1.10M.
It is up +5.29% in the last 24 hours and down -10.50% over the past month.
Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.
See More
Previous Close:
$1.70
Open:
$1.69
24h Volume:
1.10M
Relative Volume:
0.61
Market Cap:
$236.34M
Revenue:
$79,600
Net Income/Loss:
$-48.26M
P/E Ratio:
-3.6367
EPS:
-0.4922
Net Cash Flow:
$-28.24M
1W Performance:
+2.87%
1M Performance:
-10.50%
6M Performance:
+11.87%
1Y Performance:
-5.79%
1-Day Range:
$1.69
$1.80
1-Week Range:
$1.665
$1.80
52-Week Range:
$1.33
$2.365
Inhibikase Therapeutics Inc Stock (IKT) Company Profile
Name
Inhibikase Therapeutics Inc
Sector
Industry
Phone
(302) 295-3800
Address
1000 N. WEST STREET, SUITE 1200, WILMINGTON
Compare IKT vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IKT
Inhibikase Therapeutics Inc
|
1.79 | 224.46M | 79,600 | -48.26M | -28.24M | -0.4922 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Inhibikase Therapeutics Inc Stock (IKT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-04-26 | Initiated | Ladenburg Thalmann | Buy |
| Jan-21-26 | Initiated | BofA Securities | Buy |
| Dec-26-25 | Initiated | H.C. Wainwright | Buy |
| Dec-11-25 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-12-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
Inhibikase Therapeutics Inc Stock (IKT) Latest News
Inhibikase enrolls first patient in phase 3 PAH trial - MSN
Inhibikase Enrolls First Patient in Phase 3 PAH Trial - MyChesCo
Inhibikase grants stock options to five new employees - MSN
First patient enrolled in Phase 3 trial of PAH treatment IKT-001 - Pulmonary Hypertension News
MACD Signal: What is the Moat Score of Inhibikase Therapeutics IncQuarterly Growth Report & Short-Term High Return Ideas - baoquankhu1.vn
IKT Stock Price, Quote & Chart | INHIBIKASE THERAPEUTICS INC (NASDAQ:IKT) - ChartMill
Inhibikase Grants Stock Options to Five New Employees - MyChesCo
H.C. Wainwright reiterates Inhibikase stock rating on trial progress By Investing.com - Investing.com Canada
H.C. Wainwright reiterates Inhibikase stock rating on trial progress - Investing.com
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension - Sahm
Inhibikase Therapeutics Begins Enrollment for PAH Drug Trial - National Today
Inhibikase Therapeutics Enrolls First Patient in Global Phase 3 IMPROVE-PAH Study for Pulmonary Arterial Hypertension Treatment 1 - Minichart
Inhibikase enrolls first patient in Phase 3 PAH drug trial By Investing.com - Investing.com South Africa
Inhibikase Therapeutics (IKT) Begins Key Phase 3 Trial Enrollmen - GuruFocus
Inhibikase Therapeutics Enrolls First Patient In Phase 3 Trial For Pulmonary Arterial Hypertension - marketscreener.com
Inhibikase Begins Pivotal Phase 3 Trial in PAH - TipRanks
Inhibikase enrolls first patient in Phase 3 PAH drug trial - Investing.com
Inhibikase Announces First Patient Enrolled in Global Phase 3 IMPROVE-PAH Trial of IKT-001 - TradingView — Track All Markets
First patient dosed in Inhibikase (IKT) global Phase 3 IMPROVE-PAH trial of IKT-001 - Stock Titan
Springer Publishing Company & Cashmere Announce Partnership to Bring Trusted Healthcare Education Content to AI Systems - Weekly Voice
First patient enters global late-stage trial for PAH drug IKT-001 - Stock Titan
Inhibikase grants stock options to new employees under inducement plan - MSN
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Inhibikase Grants Stock Options to New Employees Under Inducement Plan - MyChesCo
IKT Technical Analysis & Stock Price Forecast - Intellectia AI
Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - 富途牛牛
Inhibikase Therapeutics Announces Inducement Grants - National Today
Inhibikase Therapeutics Grants Inducement Shares to New Hires - National Today
HC Wainwright Has Optimistic Outlook of IKT Q1 Earnings - Defense World
Nocion Therapeutics Appoints Mark Iwicki To Board - citybiz
HC Wainwright Issues Positive Estimate for IKT Earnings - MarketBeat
Inhibikase Therapeutics (IKT) Receives a Buy from H.C. Wainwright - The Globe and Mail
Death Cross: What is the next catalyst for Inhibikase Therapeutics Inc2026 Update & Safe Capital Investment Plans - baoquankhu1.vn
Inhibikase Therapeutics, Inc. 2025 Annual Report: Pipeline, Intellectual Property, and PAH Drug Development Overview - Minichart
Inhibikase Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Inhibikase Therapeutics 10-K: Operating loss $51.97M, Net loss $48.26M, Interest income $3.72M - TradingView
Inhibikase (NASDAQ: IKT) pivots to PAH drug IKT-001 with Phase 3 trial and $115M raise - Stock Titan
Inhibikase Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Inhibikase (NASDAQ: IKT) boosts cash as 2025 loss grows and PAH Phase 3 advances - Stock Titan
Inhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activity - The Manila Times
Press Release: Inhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activity - Moomoo
Form 8-KCurrent report - ADVFN
Surprises Report: What is the Moat Score of Inhibikase Therapeutics IncQuarterly Performance Summary & Entry and Exit Point Strategies - baoquankhu1.vn
Inhibikase Therapeutics Inc expected to post a loss of 10 cents a shareEarnings Preview - TradingView
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Short Interest Up 52.2% in February - MarketBeat
Aug Ideas: Does Inhibikase Therapeutics Inc stock benefit from AI growth2026 Retail & Low Drawdown Trading Techniques - baoquankhu1.vn
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Given Average Rating of "Buy" by Analysts - MarketBeat
Reviewing Athira Pharma (NASDAQ:LONA) and Inhibikase Therapeutics (NASDAQ:IKT) - Defense World
IKT Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Inhibikase Therapeutics (NASDAQ:IKT) Stock Rating Upgraded by LADENBURG THALM/SH SH - Defense World
Inhibikase Therapeutics Inc Stock (IKT) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):